Objective: To study the correlation between the response of ADRB2 (rs1042713) AA genotype to anticholinergic drugs in the treatment of children with asthma. Methods: Eighty children with ADRB2 (rs1042713) AA genotype among 237 children with asthma first diagnosed in Children’s Hospital of Kunming Medical University from Jun. 2017 to Jun. 2019 were randomly divided into the experimental group and the control group

with 40 children in each group. The experimental group was treated with inhaled glucocorticoid combined with anticholinergic drugs

while the control group received inhaled glucocorticoid combined with long-acting β2 agonist. Children’s asthma control test (C-ACT) scores

pulmonary function and drug response were compared between two groups before and after treatment. Results: After treatment

the improvements of C-ACT score and pulmonary function [forced expiratory volume in one second (FEV1)

forced vital capacity (FVC)

peak expiratory flow (PEF) and maximum midexpiratory flow (MMEF)] in the experimental group were better than those in the control group

with statistically significant differences (P<0.05). After treatment

18 out of 39 children with asthma in the experimental group responded

and 7 out of 38 children with asthma in the control group responded

the response rate of the experimental group was 3.8 times that of the control group (P<0.05

OR=3.80

95%CI: from 1.35 to 10.68). Conclusion: ADRB2 (rs1042713) gene polymorphism has different responses to drugs

and AA genotype responds better to anticholinergic drugs.